Emicizumab Classifications
Emicizumab is classified as a bispecific monoclonal antibody and a non-replacement hemophilia therapy that mimics the cofactor function of activated factor VIII. 1, 2
Pharmacological Classification
Bispecific monoclonal antibody: Emicizumab is a humanized bispecific antibody that simultaneously binds to activated factor IX (FIXa) and factor X (FX), bridging these two coagulation factors to restore hemostasis 2, 3
Factor VIII mimetic: It functions as a FVIII cofactor replacement by mimicking the role of activated FVIII (FVIIIa) in the coagulation cascade, though it binds with considerably lower affinity than natural FVIIIa 4, 2
Therapeutic Classification
Prophylactic hemostasis agent: Emicizumab is approved for routine prophylaxis to prevent bleeding episodes in hemophilia A patients 1
Non-factor therapy: Distinguished from traditional factor replacement therapies (plasma-derived or recombinant FVIII concentrates), emicizumab represents a novel class of non-replacement treatments 1
Clinical Use Categories
For hemophilia A without inhibitors: Emicizumab serves as an alternative to FVIII concentrates for prophylaxis in severe and moderately severe hemophilia A 1
For hemophilia A with inhibitors: Emicizumab is preferred over bypassing agents (recombinant FVIIa and activated prothrombin complex concentrate) for prophylaxis 1
Administration Classification
Subcutaneous therapy: Unlike intravenous FVIII concentrates, emicizumab is administered subcutaneously with flexible dosing schedules (weekly, biweekly, or every 4 weeks) 1
Long-acting prophylaxis: With an approximately 1-month half-life and linear pharmacokinetics, emicizumab maintains effective trough concentrations throughout extended dosing intervals 2
Important Distinction
Emicizumab is not classified as a bypassing agent, despite being used in patients with inhibitors. Bypassing agents include recombinant FVIIa and activated prothrombin complex concentrate, which work through different mechanisms 1. This distinction is clinically critical because concomitant use of emicizumab with activated prothrombin complex concentrate carries thrombotic risk, whereas recombinant FVIIa is the preferred bypassing agent when breakthrough bleeding occurs on emicizumab prophylaxis 1.